Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours.
biomarkers
ciliated cell
differentiation
endometrial carcinoma
organoids
single cell sequencing
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
12
03
2020
revised:
11
06
2020
accepted:
14
07
2020
pubmed:
21
7
2020
medline:
15
12
2020
entrez:
21
7
2020
Statut:
ppublish
Résumé
Endometrial carcinoma, the most common gynaecological cancer, develops from endometrial epithelium which is composed of secretory and ciliated cells. Pathologic classification is unreliable and there is a need for prognostic tools. We used single cell sequencing to study organoid model systems derived from normal endometrial endometrium to discover novel markers specific for endometrial ciliated or secretory cells. A marker of secretory cells (MPST) and several markers of ciliated cells (FAM92B, WDR16, and DYDC2) were validated by immunohistochemistry on organoids and tissue sections. We performed single cell sequencing on endometrial and ovarian tumours and found both secretory-like and ciliated-like tumour cells. We found that ciliated cell markers (DYDC2, CTH, FOXJ1, and p73) and the secretory cell marker MPST were expressed in endometrial tumours and positively correlated with disease-specific and overall survival of endometrial cancer patients. These findings suggest that expression of differentiation markers in tumours correlates with less aggressive disease, as would be expected for tumours that retain differentiation capacity, albeit cryptic in the case of ciliated cells. These markers could be used to improve the risk stratification of endometrial cancer patients, thereby improving their management. We further assessed whether consideration of MPST expression could refine the ProMiSE molecular classification system for endometrial tumours. We found that higher expression levels of MPST could be used to refine stratification of three of the four ProMiSE molecular subgroups, and that any level of MPST expression was able to significantly refine risk stratification of the copy number high subgroup which has the worst prognosis. Taken together, this shows that single cell sequencing of putative cells of origin has the potential to uncover novel biomarkers that could be used to guide management of cancers. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-214Informations de copyright
© 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Références
More IA, Masterton RG. The role of oestrogen in the control of ciliated cells of the human endometrium. J Reprod Fertil 1976; 47: 19-24.
Fleming S, Tweeddale DN, Roddick JW Jr. Ciliated endometrial cells. Am J Obstet Gynecol 1968; 102: 186-191.
Masterton R, Armstrong EM, More IA. The cyclical variation in the percentage of ciliated cells in the normal human endometrium. J Reprod Fertil 1975; 42: 537-540.
Wang W, Vilella F, Moreno I, et al. Single cell RNAseq provides a molecular and cellular cartography of changes to the human endometrium through the menstrual cycle. Fertil Steril 2018; 110(Suppl): e2.
Schueller EF. Ciliated epithelia of the human uterine mucosa. Obstet Gynecol 1968; 31: 215-223.
Zhang S, Zhang T, Dolgalev I, et al. Both fallopian tube and ovarian surface epithelium can act as cell-of-origin for high grade serous ovarian cancer. bioRxiv 2019; 481200. Not peer reviewed.
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014; 15: e268-e278.
Lu Y, Cuellar-Partida G, Painter JN, et al. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet 2015; 24: 5955-5964.
Lee AW, Templeman C, Stram DA, et al. Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril 2016; 105: 35-43 e1-10.
Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-394.
Baekelandt MM, Castiglione M, ESMO Guidelines Working Group. Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(suppl 4): 29-31.
Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001; 82: 371-374.
Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751.
Kong TW, Chang SJ, Paek J, et al. Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria. J Gynecol Oncol 2015; 26: 32-39.
Kwon JS, Qiu F, Saskin R, et al. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer? Obstet Gynecol 2009; 114: 736-743.
Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008; 109: 11-18.
Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013; 37: 874-881.
Hoang LN, McConechy MK, Kobel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 2013; 37: 1421-1432.
Soslow RA. High-grade endometrial carcinomas - strategies for typing. Histopathology 2013; 62: 89-110.
Wright JD, Barrena Medel NI, Sehouli J, et al. Contemporary management of endometrial cancer. Lancet 2012; 379: 1352-1360.
Kobel M, Ronnett BM, Singh N, et al. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol 2019; 38(suppl 1): S123-S131.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016; 22: 4215-4224.
Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015; 28: 836-844.
Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299-310.
Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017; 123: 802-813.
Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29: 1180-1188.
Karnezis AN, Leung S, Magrill J, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res 2017; 3: 279-293.
Talhouk A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol 2016; 143: 46-53.
Guseh JS, Bores SA, Stanger BZ, et al. Notch signaling promotes airway mucous metaplasia and inhibits alveolar development. Development 2009; 136: 1751-1759.
Kessler M, Hoffmann K, Brinkmann V, et al. The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat Commun 2015; 6: 8989.
Xie Y, Park ES, Xiang D, et al. Long-term organoid culture reveals enrichment of organoid-forming epithelial cells in the fimbrial portion of mouse fallopian tube. Stem Cell Res 2018; 32: 51-60.
Gomperts BN, Gong-Cooper X, Hackett BP. Foxj1 regulates basal body anchoring to the cytoskeleton of ciliated pulmonary epithelial cells. J Cell Sci 2004; 117: 1329-1337.
You Y, Huang T, Richer EJ, et al. Role of f-box factor foxj1 in differentiation of ciliated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 286: L650-L657.
Huang T, You Y, Spoor MS, et al. Foxj1 is required for apical localization of ezrin in airway epithelial cells. J Cell Sci 2003; 116: 4935-4945.
La Manno G, Soldatov R, Zeisel A, et al. RNA velocity of single cells. Nature 2018; 560: 494-498.
Nagahara N. Multiple role of 3-mercaptopyruvate sulfurtransferase: antioxidative function, H2S and polysulfide production and possible SOx production. Br J Pharmacol 2018; 175: 577-589.
Kimura Y, Koike S, Shibuya N, et al. 3-Mercaptopyruvate sulfurtransferase produces potential redox regulators cysteine- and glutathione-persulfide (Cys-SSH and GSSH) together with signaling molecules H2S2, H2S3 and H2S. Sci Rep 2017; 7: 10459.
Li FQ, Chen X, Fisher C, et al. BAR domain-containing FAM92 proteins interact with Chibby1 to facilitate ciliogenesis. Mol Cell Biol 2016; 36: 2668-2680.
Hirschner W, Pogoda HM, Kramer C, et al. Biosynthesis of Wdr16, a marker protein for kinocilia-bearing cells, starts at the time of kinocilia formation in rat, and wdr16 gene knockdown causes hydrocephalus in zebrafish. J Neurochem 2007; 101: 274-288.
Wang X, Lou Z, Dong X, et al. Crystal structure of the C-terminal domain of human DPY-30-like protein: a component of the histone methyltransferase complex. J Mol Biol 2009; 390: 530-537.
Zhang AW, O'Flanagan C, Chavez EA, et al. Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nat Methods 2019; 16: 1007-1015.
Hughes CS, McConechy MK, Cochrane DR, et al. Quantitative profiling of single formalin fixed tumour sections: proteomics for translational research. Sci Rep 2016; 6: 34949.
Ji JX, Cochrane DR, Tessier-Cloutier B, et al. Use of immunohistochemical markers (HNF-1beta, Napsin A, ER, CTH, and ASS1) to distinguish endometrial clear cell carcinoma from its morphologic mimics including arias-stella reaction. Int J Gynecol Pathol 2020; 39: 344-353.
Lac V, Nazeran TM, Tessier-Cloutier B, et al. Oncogenic mutations in histologically normal endometrium: the new normal? J Pathol 2019; 249: 173-181.
Moore L, Leongamornlert D, Coorens THH, et al. The mutational landscape of normal human endometrial epithelium. Nature 2020; 580: 640-646.
Ghosh A, Syed SM, Tanwar PS. In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells. Development 2017; 144: 3031-3041.
Hu Z, Artibani M, Alsaadi A, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. bioRxiv 2019; 672626v1. Not peer reviewed.
Aung KL, El-Khoueiry AB, Gelmon K, et al. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Invest New Drugs 2018; 36: 1026-1036.
Massard C, Azaro A, Soria JC, et al. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol 2018; 29: 1911-1917.
Cook N, Basu B, Smith DM, et al. A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 2018; 118: 793-801.
Locatelli MA, Aftimos P, Dees EC, et al. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget 2017; 8: 2320-2328.
Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005; 366: 491-505.
Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001; 6: 47-86.
Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-649.
Stelloo E, Nout RA, Naves LC, et al. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. Gynecol Oncol 2014; 133: 197-204.
Abdulfatah E, Wakeling E, Sakr S, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: towards early personalized patient management. Gynecol Oncol 2019; 154: 467-474.
Bergen V, Lange M, Peidli S, et al. Generalizing RNA velocity to transient cell states through dynamical modeling. bioRxiv 2019; 820936v1. Not peer reviewed.
Schelker M, Feau S, Du J, et al. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nat Commun 2017; 8: 2032.
Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12: 453-457.
Mura M, Swain RK, Zhuang X, et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 2012; 31: 293-305.
Espagnolle N, Guilloton F, Deschaseaux F, et al. CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med 2014; 18: 104-114.
Shih AJ, Menzin A, Whyte J, et al. Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. PLoS One 2018; 13: e0206785.
Rawstron AC. Immunophenotyping of plasma cells. Curr Protoc Cytom 2006; 36: 6.23.1-6.23.14.
Medina FA, Williams TM, Sotgia F, et al. A novel role for caveolin-1 in B lymphocyte function and the development of thymus-independent immune responses. Cell Cycle 2006; 5: 1865-1871.
Perisic Matic L, Rykaczewska U, Razuvaev A, et al. Phenotypic modulation of smooth muscle cells in atherosclerosis is associated with downregulation of LMOD1, SYNPO2, PDLIM7, PLN, and SYNM. Arterioscler Thromb Vasc Biol 2016; 36: 1947-1961.
Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012; 10: 51.